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HBV Genotype B Is Associated With Better Response 
to Interferon Therapy in HBeAg(+) Chronic 
Hepatitis Than Genotype C 
Chun Tao Wai, Chi-Jen Chu, Munira Hussain, and Anna S. F. Lok 
Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been impli- 
cated in spontaneous and interferon alfa (IFN-+related hepatitis B e antigen (HBeAg) 
seroconversion. We performed a retrospective analysis of a previously reported randomized 
controlled trial to determine the effects of HBV genotype and precore/core promoter muta- 
tions on IFN-c~ response in patients with HBeAg-positive chronic hepatitis. Clinical data 
and stored sera from 109 (95%) patients in the original trial were analyzed. Seventy-three 
patients received IFN-a and 34 received no treatment (controls). Almost all patients had 
HBV genotypes B (38%) and C (60%). Antiviral response was achieved in 39% and 17% of 
IFN-a-treated patients (P = .03) and in 10% and 8% of untreated controls (1" = 38)  with 
HBV genotype B and C, respectively. Multivariate analysis identified HBV genotype B, 
elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV- 
DNA levels but not IFN-a treatment as independent factors associated with antiviral re- 
sponse. Among the 66 patients with elevated pretreatment ALT level, antiviral response was 
achieved in 57% and 21% of IFN-a-treated patients (P = .019), and in 25% and 8% of 
untreated controls (P = .45) with HBV genotype B and C, respectively. Multivariate analysis 
showed that genotype B and low pretreatment HBV-DNA levels were independent predic- 
tors of antiviral response. In conclusion, our data showed that HBV genotype B was associ- 
ated with a higher rate of IFN-induced HBeAg clearance compared with genotype C. 
Stratification for HBV genotypes should be considered in future clinical trials of antiviral 
therapy of chronic hepatitis B. (HEPATOLOGY 2002;36:1425-1430.) 
nterferon alfa (IFN-a) and lamivudine are the 2 cur- 
rently approved treatments for chronic hepatitis B I (CHB) in most countries.' Both agents have limited 
long-term efficacy. IFN-a is associated with significant 
adverse effects, whereas long-term therapy with lamivu- 
dine may result in drug resistance. Thus, optimal patient 
selection for treatment is important. High pretreatment 
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alanine aminotransferase (ALT) levels have been found to 
be the most important predictor of response to both 
IFN-a and lamivudine therapy.2-4 Low pretreatment se- 
rum hepatitis B virus (HBV)-DNA levels also have been 
shown to be a predictor of response in many studies on 
IFN-a thera~y.~.3 
Recently, HBV genotypes and precore and core pro- 
moter variants have been implicated in spontaneous hep- 
atitis B e antigen (HBeAg) seroconversion as well as 
response to antiviral treatment. HBV can be classified 
into 7 genotypes (A to G).5 Genotype A is more common 
in North America and northwestern Europe; genotypes B 
and C are mainly found in Asia; genotype D is predomi- 
nant in the Mediterranean area, Middle East, and India; 
whereas the distribution of genotypes E, F, and G is less 
well studied.6 Genotype A was found to be associated with 
a higher rate of IFN-a-induced HBeAg seroconversion 
than genotype D (37% vs. 6%, P = .03) in a study of 64 
German patients with HBeAg-positive CHB.7 Another 
study of 58 Taiwanese patients who received IFN-a treat- 
ment for HBeAg-positive CHB found that patients with 
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genotype B had a significantly higher rate of HBeAg loss 
compared with those with genotype C (41% vs. 15%, P = 
.045).* In the German study, a high number of mutations 
in the core promoter region and pretreatment HBV- 
DNA level of less than 10 pg/mL also were associated with 
better response whereas in the Taiwan study, younger age 
was the only other factor associated with a higher rate of 
response. Both studies did not include an untreated 
group. Thus, it is not clear if IFN-a treatment had an 
incremental effect on HBeAg seroconversion when HBV 
genotype was controlled for. 
The 2 most well-defined, naturally occurring HBV 
mutations are the point mutation in the precore region 
(G189&), creating a stop at codon 28, and the dual mu- 
tation A1762T/G176& at the basic core promoter region.9 
Precore and core promoter mutations have been found to 
precede or emerge at the time of HBeAg seroconversion 
and to affect response to IFN-a therapy. In previous stud- 
ies using direct sequencing, we showed that HBeAg-pos- 
itive patients with detectable precore and core promoter 
mutations were more likely to undergo spontaneous 
HBeAg clearance.1° Presence of precore mutations also 
was associated with a higher rate of response to IFN-a 
therapy (55% vs. 17%, P = .04) as compared with those 
without precore mutations.' However, other studies in- 
volving a smaller number of patients showed that the rate 
of IFN-a-induced HBeAg seroconversion was not re- 
lated to presence of precore stop codon m~tations.1~~13 
Two studies, one involving German and another involv- 
ing Chinese patients, found that presence of core pro- 
moter mutations was associated with a higher rate of IFN- 
a-induced HBeAg loss, whereas a third study from 
Germany failed to confirm this finding.7.'*,'5 These con- 
flicting results may be caused by differences in patient 
characteristics, pretreatment ALT levels, and other viro- 
logic factors such as HBV genotypes. Almost all the ear- 
lier-mentioned studies included small numbers of 
patients and examined only a few potential predictors. 
Thus, further studies involving a larger number of pa- 
tients are needed to identify independent predictors of 
response to IFN-a treatment. In addition, a parallel con- 
trol group should be included to determine if IFN-a has 
any incremental benefit when baseline factors are con- 
trolled. 
The effect of HBV genotype on response to nucleo- 
s( t)ide analogues is less clear because few studies have been 
reported to date. Of 43 (33 HBeAg positive and I0 
HBeAg negative) CHB patients treated with lamivudine, 
those with ayw subtype had a trend toward better viro- 
logic and biochemical response than those with adw sub- 
type.16 In another study on 31 HBeAg-positive CHB 
patients treated with lamivudine, no significant difference 
in HBeAg seroconversion was seen in patients with HBV 
genotype B or C.l7 Finally, a recent study of 1,032 CHB 
(both HBeAg positive and negative) patients treated with 
adefovir dipivoxil showed no difference in viral load re- 
duction after 48 weeks of treatment.18 
We performed a retrospective analysis of a previously 
reported randomized controlled trial to determine the ef- 
fects of HBV genotype, precore/core promoter muta- 
tions, as well as demographic factors and pretreatment 
ALT and HBV-DNA levels, on IFN-a response in Chi- 
nese patients with HBeAg-positive CHB. 
Patients and Methods 
Patients. Clinical data and stored sera from a placebo- 
controlled trial comparing IFN-a with and without pred- 
nisone versus placebo were studied.'9 All patients were 
ethnic Chinese with the presence of hepatitis B surface 
antigen in serum for more than 6 months, and detectable 
HBeAg and serum HBV DNA (by direct spot hybridiza- 
tion). They were randomized to receive IFN-a with pred- 
nisone priming, IFN-a only, or no treatment (controls). 
Prednisone priming was given orally in daily doses of 45, 
30, and 15 mg each for 2 weeks, followed by a 2-week rest 
before administration of IFN-a. Interferon a-2b (Intron 
A; Schering Plough, Kenilworth, NJ) was administered 
subcutaneously for 16 weeks in doses of 10 MU 3 times 
weekly. Liver biopsies were performed within 6 months of 
entry and again at month 12. Antiviral response was de- 
fined as sustained clearance of serum HBV DNA by direct 
spot hybridization (lower limit of detection of 10 pg/mL) 
and clearance of HBeAg at month 12. 
Serohgic Testing. Hepatitis B serologic markers: hep- 
atitis B surface antigen, HBeAg, and hepatitis B e antibody 
were tested by using commercially available enzyme-linked 
immunosorbent assay kits from Abbott Laboratories (North 
Chicago, IL). 
HBV Genotype, Precore, and Core Promoter Mu- 
tations. Residual sera collected within 6 months before 
entry, which were stored at -70°C were retrieved. HBV 
genotypes, precore (G1894) and core promoter (A1762T 
and G1764A) mutations, were determined by line-probe 
assay (Inno-Lipa, Innogenetics Inc., Ghent, Belgium) as 
described previously.20 Comparison of the results of the 
line-probe assay and direct sequencing showed a concor- 
dance rate of 100% for HBV genotypes and greater than 
95% for precore and core promoter mutations.21,22 
Quantification of HBV DNA. Serum HBV-DNA 
level was quantified by a polymerase chain reaction assay 
with a lower limit of detection of 200 copies/mL and a 
linearity range of 2 X 102 to 2 X 105 copies/mL (Cobas 
Amplicor HBV Monitor, Roche Diagnostic Systems, 
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Table 1. Demographic and Clinical Characteristics of Patients With or Without IFN Treatment 
IFN-a + IFN-a NO IFN-a 
Controls Prednlsone Primlng Prednlsone Primlng Combined 
(n = 34) (n = 36) (n = 39) (n = 75)  
Age, yr 29 2 1 30 ? 1 30 f 1 30 2 1 
Sex: Male 20 (59%) 24 (67%) 25 (64%) 49 (66%) 
Pretreatment ALT level, U/L 82 f 14 103 2 15 133 2 25 118 f 15 
No. with elevated pretreatment ALT 16 (47%) 25 (69%) 27 (69%) 52 (69%)* 
8.59 t 0.14 Pretreatment HBV DNA, log,, copies/mL 8.96 2 0.17 8.56 ? 0.18 8.63 f 0.20 
Pretreatment histology showing cirrhosis 4 (12%) 3 (8%) 5 (13%) 8 (11%) 
Genotype 
B 10 (29%) 17 (47%) 14 (36%) 31 (41%) 
C 24 (71%) 17 (47%) 25 (64%) 42 (56%) 
D 0 2 (6%) 0 2 (3%) 
Precore mutation 
G1896A 6 (18%) 16 (44%) 13 (33%) 29 (39%)t 
G1898A 1(3%) 0 0 0 
Core promoter mutation 
A1762Tt G1764A 12 (35%) 12 (33%) 15 (39%) 27 (36%) 
Deletion 2 (6%) l ( l%)  0 1(1%) 
Single mutation (A1762T or G1764A) 0 2 (3%) 0 2 (3%) 
21 (28%)+ Antiviral response 3 (9%) 13 (31%) 10 (26%) 
Comparisons between IFN-treated patients and controls: 
' P  = ,033. 
t P  = ,038. 
tP = ,064. 
Inc., Pleasanton, CA). All samples were prediluted up to 
10' times. A 100,000-fold dilution was used for the initial 
testing of all samples as recommended by the manufac- 
turer's manual. Retesting with either a higher or lower 
dilution was performed when results of the initial testing 
were out of the range o f  linearity of the assay. 
Statistical Ana&sis. Results were expressed as 
mean & standard error of mean. Data were analyzed by 
using SPSS version 10.0 software package (SPSS Inc., 
Chicago, IL). Categoric variables were compared by the 
x2 test. Continuous variables were compared by the Stu- 
dent's t test. Multivariate analysis using stepwise logistic 
regression was performed to identify independent factors 
associated with IFN-a response. Results were considered 
statistically significant at P < .05. 
Patient Characteristics. Sera collected within 6 
months before entry were successfully retrieved in 103 
(95%) of the original 115 patients. Among these 103 
patients, 75 (69%) were treated with IFN-a (36 with and 
39 without prednisone priming), 12 (1 I%) had cirrhosis 
on biopsy at entry, and 68 (62%) had elevated ALT levels 
at baseline. Twenty-four (22%) patients had an antiviral 
response. Demographic and clinical characteristics of 
IFN-a-treated patients and controls are shown in Table 
I .  Because the rates of antiviral response in the 2 IFN-a 
treatment arms were similar,'9 these 2 groups were com- 
bined in the subsequent analysis. 
HBV Genotype, Precore, and Core Promoter Mu- 
tations. Forty-one (38%) patients had genotype B, 66 
(60%) had genotype C,  and 2 (2%) had genotype D. 
Thirty-five (32%) patients had precore stop codon 
(G189&) mutation. Of these, 23 had predominant wide- 
type precore sequence, 6 had an equal mix of wide-type 
and variant sequence, and 6 had predominant variant 
sequence. Thirty-nine (36%) patients had dual core pro- 
moter (A1762T and G176&) mutations. Of these, 8 had 
predominant wide-type core promoter sequence, 2 1 had 
an equal mix of wide-type and variant sequence, and 10 
had predominant variant sequence. 
Comparison Between Genotype B and C Patients. 
At entry, the 2 groups were comparable in age, and pre- 
treatment HBV-DNA and ALT levels, but patients with 
genotype B had a higher prevalence of precore and a lower 
prevalence of core promoter mutations (Table 2). The 
gender distribution in the 2 groups also was different, 
being equal among patients with genotype B and male 
predominant among patients with genotype C. 
Patients with HBV genotype B had a significantly higher 
rate of antiviral response to IFN-a, 33% versus 17% among 
patients with genotype C (P = .03) (Table 2). 
Factors Associated With H B d g  Clearance. Factors 
associated with HBeAg clearance within 12 months of 
entry into the study among the 107 patients with geno- 
type B and C were analyzed. HBV genotype B, elevated 
pretreatment ALT level, low pretreatment HBV-DNA 
level, and treatment with IFN-a were found to be significant 
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Table 2. Comparison of Patients With HBV 
Genotype B and C 
Genotype B Genotype C 
(n = 41) (n = 66) P 
Age, yr 30 f 1 29 t 1 NS 
Sex: male 21 (51%) 47 (71%) ,042 
Pretreatment ALT, U/L 8 6 k  11 120% 17 .08 
No. with elevated pretreatment ALT 
level 25(61%) 41 (62%) NS 
Pretreatment HBV DNA, log10 
copies/mL 8.85 2 0.16 8.60 i- 0.14 NS 
Pretreatment histology showing 
cirrhosis 4 (10%) 8(12%) NS 
Precore GLa96A mutation 18 (44%) 15 (23%) ,041 
Core promoter A1762T. G1764A 
mutation 5 (12%) 33 (50%) c.001 
Treatment with IFN-a 31(76%) 42(64%) NS 
Antiviral response 13 (32%) 9(14%) ,029 
IFN-(U treatment 12/31 (39%) 7/42 (17%) ,034 
No treatment 1/10 (10%) 2/24 (8%) NS 
Abbreviation: NS, not significant. 
predictors of HBeAg clearance in univariate analysis (Table 
3). Multivariate analysis with stepwise logistic regression 
identified HBV genotype B (odds ratio [OR], 1.28; 95% 
confidence interval [CI], 1.06-1.42; P = .006), low pretreat- 
ment HBV-DNAlevel (OR, 1.10; 95% CI, 1.03-1.17; P =  
.007), and elevated pretreatment ALT level (OR, 1.22; 95% 
CI, 1.05-1.42; P = .01 l), but not IFN-a treatment as inde- 
pendent factors associated with HBeAg clearance. 
Among the 75 patients who were treated with IFN-a, 
low pretreatment HBV-DNA, and elevated pretreatment 
ALT levels were significant predictors of antiviral re- 
sponse in univariate analysis whereas HBV genotype B 
was borderline significant (Table 4). All 3 factors were 
Table 3. Univariate Analysis of Factors Associated 
With HBeAg Clearance Among All Patients 
HBeAg No HBeAg 
Clearance Clearance 
(n = 19) (n = 54) P 
~ ~~ ~ 
Age. yr 
Sex. male 
Pretreatment ALT level, U/L 
No with elevated pretreatment ALT 
Pretreatment HBV DNA, loglo 








Precore G1896A mutation 
Core promoter A1752T, G1764A 
mutation 
Treatment with IFN-a 
~~ 
30 f 1 
146 ? 20 
16 (73%) 
20 (91%) 








29 2 1 
52 (61%) 
97 i 13 
46 (54%) 


















Table 4. Univariate Analysis of Factors Associated With 
Antiviral Response Among Patients Treated With IFN 
Responder Nonresponder 
(n = 19) (n = 54) P 
Age. yr 
Sex: male 
Pretreatment ALT level, U/L 
No. with elevated pretreatment ALT 
Pretreatment HBV DNA, log10 







Precore GIa96A mutation 
Core promoter A1762T, G1764A 
Prednisone priming 
mutation 
31 i 1 
14 (74%) 
151 I+_ 22 
18 (95%) 







29 t: 1 
34 (63%) 
107 t: 19 
32 (59%) 

















found to be significant predictors of antiviral response in 
multivariate analysis. 
Patients With Elevated Pretreatment ALT Levels. 
Of the 66 patients with elevated pretreatment ALT levels, 20 
(30%) had HBeAg clearance. Antiviral response was 
achieved in 57% and 2 1% of IFN-a-treated patients (P = 
.Ol9), and in 25% and 8% of untreated controls (P = .45) 
with HBV genotype B and C, respectively (Fig. 1). Multi- 
variate analysis showed that genotype B (OR, 1.47; 95% CI, 
1.18-1.82; P = .001) and low pretreatment HBV-DNA 
level (OR, 1.10; 95% CI, 1.01-1.21; P = .029) were inde- 
pendent predictors of HBeAg clearance. 
Patients With Normal Pretreatment ALT Levels. 
Antiviral response was uniformly low among the 41 pa- 
tients with normal ALT levels. None of the 16 patients 
P = 0 0 1 9  
7 - 1  P = 0.42 1 
40% 
C 
0 2 30% 
c--- P=045 
' P = 0 3 2  I 
B C 
Genotype 
I untreated 0 IFN treated1 
Fig. 1. Antiviral response rates in patients with elevated ALT levels in 
HBV genotypes B and C. , untreated; 0, IFN treated. 
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with genotype B (10 IFN-a treated and 6 controls), and 
only 2 of the 25 patients with genotype C (1 of 13 IFN-a 
treated and 1 of 12 controls) had an antiviral response. 
Discussion 
Our study confirmed a previous report from Taiwans 
that HBV genotype B is associated with a higher rate of 
antiviral response to IFN-a treatment than HBV geno- 
type C among Chinese patients with HBeAg-positive 
CHB. The absence of a control group in the Taiwan study 
and the finding of a higher rate of spontaneous HBeAg 
seroconversion in patients with genotype B,20 raise ques- 
tions as to whether the better response in patients with 
genotype B is attributed to the IFN-a treatment. In this 
study, IFN-a treatment increased the antiviral response 
in patients with both genotype B (39% vs. 10%) and C 
(17% vs. SYo), compared with untreated patients with the 
same genotype, but these differences did not reach statis- 
tical significance. The lack of statistical significance be- 
tween treated patients and controls may be related to the 
small sample size. However, multivariate analysis with 
stepwise logistic regression identified HBV genotype B 
and not IFN-a treatment as an independent factor pre- 
dictive of antiviral response, suggesting that the addi- 
tional benefit of IFN-a treatment is small in patients who 
are likely to undergo spontaneous HBeAg seroconversion. 
We found that the presence of precore stop codon 
mutation at entry was associated with a higher rate of 
antiviral response on univariate analysis. This is in accord 
with our previous analysis using a less sensitive tech- 
nique- direct sequencing-to detect the precore stop 
codon mutation.' 1 Direct sequencing is unable to identify 
minor amounts ofvariant viruses in a background ofwild- 
type sequence~.~3 The use of a line-probe assay increases 
the sensitivity of detection of precore variants, which ex- 
plains the higher rate of precore stop codon mutation 
detected in this study (32%) than in our previous study 
(7%). Precore stop codon mutation usually is selected 
around the time of HBeAg seroconversion. Thus, 
HBeAg-positive patients with detectable precore stop 
codon mutation may be on the verge of spontaneous 
HBeAg seroconversion. Whether IFN-a treatment has- 
tened this process is unclear. Precore stop codon mutation 
was not an independent factor predictive of antiviral re- 
sponse on multivariant analysis. This may be related to 
the association between precore stop codon mutation and 
HBV genotype B, with the latter being a more important 
factor. Alternatively, precore stop codon variant, when 
present as a minor species, is less predictive of imminent 
HBeAg seroconversion than when it is present as the pre- 
dominant viral species. In this study, presence of the dual 
core promoter mutation at entry was not related to anti- 
viral response. Although our study is larger than previous 
studies, the role of core promoter mutation on response to 
IFN-a and other antiviral therapy should be further ex- 
amined. 
We confirmed that elevated pretreatment ALT and 
low pretreatment HBV-DNA levels were independent 
predictors of antiviral resp0nse.~,3 Elevated pretreatment 
ALT level also was found to be the most important pre- 
dictive factor of response to lamivudine treatment among 
patients with HBeAg-positive CHB.* Our results support 
recommendations from the American Association for the 
Study of Liver Diseases and the Asian Pacific Association 
for the Study of the Liver that patients with normal pre- 
treatment ALT levels should not be treated because the 
response to currently available treatment is p o ~ r . ~ * , ~ ~  
In summary, our study showed that in addition to low 
pretreatment HBV DNA and elevated pretreatment ALT 
levels, HBV genotype B was associated with a higher rate 
of antiviral response to IFN-a treatment in Chinese pa- 
tients with HBeAg-positive CHB than genotype C. Fur- 
ther studies are needed to determine if HBVgenotype also 
plays a role in response to IFN-a treatment in chronic 
hepatitis B patients from other geographic regions where 
other HBV genotypes prevail. More importantly, the role 
of HBV genotypes in response to nucleos(t)ide treatment 
of HBeAg-positive as well as HBeAg-negative CHB 
should be examined. Careful analysis of these data may 
lead to better selection of CHB patients for antiviral treat- 
ment and possibly development of therapeutic regimens 
tailored to viral genotype as in the case of hepatitis C. 
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